Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2

Damian Mojsak; Beata Kuklińska; Michał Dębczyński; Robert Marek Mróz

doi:10.5114/wo.2021.105031

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2021
vol. 25

Send email

Copy url:

abstract:

Review paper

Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2

Damian Mojsak

¹

,

Beata Kuklińska

¹

,

Michał Dębczyński

¹

,

Robert Marek Mróz

¹

Second Department of Lung Diseases and Tuberculosis, Medical University of Białystok, Białystok, Poland

Contemp Oncol (Pozn) 2021; 25 (1): 53-56

DOI: https://doi.org/10.5114/wo.2021.105031

Online publish date: 2021/04/06

View full text Get citation

PlumX metrics:

Immunotherapy is a new and very promising method of anti-cancer treatment. Unfortunately, not every patient can benefit from this treatment. The Polish drug program determines the selection of patients based on PD-L1 expression and the performance status assessed with the use of Eastern Cooperative Oncology Group Performance Status (ECOG PS) score. Patients with ECOG PS 2 represent a significant proportion of the cancer population, one which is overlooked in most clinical trials of immunotherapy. Often, a reduced performance status is the only factor that excludes the patient from treatment with immunotherapy. Choosing the optimal method of treatment in patients with a worse general condition and with multiple diseases may be a significant problem for the doctor. Assessment of performance status may be a particular problem because not every patient has a worse PS score for the same reasons. In this study, we analyse the results of treatment of patients with a poorer performance status to date, and we present tools that improve the precise assessment of the degree of the performance status, which may enable more patients to access novel lung cancer treatments.

keywords:

Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2

Damian Mojsak 1 , Beata Kuklińska 1 , Michał Dębczyński 1 , Robert Marek Mróz 1

non-small cell lung cancer, immunotherapy, performance status

Damian Mojsak

¹

,

Beata Kuklińska

¹

,

Michał Dębczyński

¹

,

Robert Marek Mróz

¹